Exicure, Inc. Common Stock
XCUR
Closed
$1.76
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The company is headquartered in Chicago, Illinois and currently employs 8 full-time employees. The company went IPO on 2018-05-09. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The firm is also exploring strategic alternatives to maximize stockholder value.
Key stats
Open
$2.00
Volume
83.73K
Market cap
$13.83M
Prev. close
$1.90
Impl / hst vl
-
Open interest
$0.00
$1.76
Day’s Range
$2.00
$1.68
52W Range
$6.65
Valuation
22
Valuation score
Overvalued
P/E
-
P/S
-
P/B
6.30
Current ratio
0.79
Debt / Equity
-1.24
ROE
-179.41%
Gross margin
-
Income growth
-36.92%
FCF growth
22.27
Analysts estimates
Consensus rating
Hold
The average rating from top 3 analysts indicates that stock may significantly underperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.04
The top 3 analysts forecasts that 12-month price may increase by 15.91%, with a low of $2.02 and a high of $2.10
$2.02
Low
$2.04
Avg
$2.10
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$1.83M
Revenue
Net income
Previous EPS
-Estimate EPS
$0.00
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply